# US 2019/0315806 A1 · Polymyxin derivative, preparation method and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315806 A1
- Document ID: US20190315806A1
- Status: Published application
- Kind: A1
- Application number: 16/468,997
- Filed: 2017-12-15
- Published: 2019-10-17
- Earliest claimed: 2016-12-16
- Assignees: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
- Applicants: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
- Inventors: ALONG CUI; ZHUORONG LI; JIE JIN; YAN GAO; XINXIN HU; XUEFU YOU; YANG CHEN; QIYANG HE
- Web page: https://patentgrep.com/patent/US20190315806A1

## CPC

- C07K 7/62: Polymyxins; Related peptides
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61P 31/04: Antibacterial agents
- C07K 1/061: {using protecting groups}
- C07K 1/12: by hydrolysis {, i.e. solvolysis in general}
- C07K 1/30: by precipitation
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Provided are a polymyxin derivative having a general formula I structure, and a preparation method and an application thereof. The method for preparing the polymyxin derivative comprises the following steps: (1) an Fmoc-AA-OP side chain free amino group of a protected basic amino acid reacting with a halogenated resin to obtain an Fmoc-AA-OP-resin; (2) the Fmoc-AA-OP-resin being coupled one by one to obtain a linear peptide-resin; (3) the linear peptide-resin selectively removing a protective group, and carrying out solid-phase cyclization to obtain a cyclic peptide-resin; (4) the cyclic peptide-resin undergoing acidic hydrolysis and ether precipitation to obtain a crude product of a cyclic polypeptide; (5) the crude product being purified and/or salt transferred and lyophilized to obtain a pure product of the cyclic polypeptide. The polymyxin derivative may be used for preparing an antibacterial drug, and used in particular for preparing an antibacterial drug having an expanded antibacterial spectrum, improved antibacterial activity and reduced renal toxicity, comprising preparing an antibacterial drug against a “superbugs” which carries the NDM-1 gene.

## Claims

### Claim at position 1

1-2. (canceled)

### Claim at position 2

3: A polymyxin derivative having the structure of formula II or a pharmaceutically acceptable salt thereof,
wherein R0 is selected from the group consisting of CH3—O—(CH2)m—, m=4-10; (CH3)2—N—(CH2)m—, m=4-10; CH3—(CH2)n—CO—CH2—, n=2-9,
wherein R10 is a phenyl group, or the p-position of the phenyl group connected to O attached to R10 is substituted with a (C1-C4)-linear alkyl group, for example, the p-position of the phenyl group connected to —O— attached to R10 is substituted with methyl; hydroxy substituted (C7-C12)-branched alkyl, for example, 2-hydroxy-5-methylheptyl;
R1 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2;
R2 is —CH(CH3)OH;
R3 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2;
the amino acid at position-3 is L-configuration,
R4 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2;
R5 is —CH2—R11; R11 is phenyl;
the amino acid at position-6 is D-configuration,
R6 is (C3-C8)-branched alkyl, for example, isobutyl;
R7 is NH2—(CH2)y—, wherein y is an integer from 1 to 4, for example, 2;
R8 is NH2—(CH2)y—, wherein y is an integer from 1 to 4, for example, 2;
R9 is —CH(CH3)OH; and
wherein Compounds 8 and 10 are not included.

### Claim at position 3

4: A polymyxin derivative having the structure of formula II or a pharmaceutically acceptable salt thereof,
wherein R0 is selected from the group consisting of CH3—O—(CH2)m—, m=4-10; (CH3)2—N—(CH2)m—, m=4-10; CH3—(CH2)n—CO—CH2—, n=2-9;
R10 is the p-position of the phenyl group connected to O attached to R10 is substituted with a (C1-C4)-linear alkyl group, for example, the p-position of the phenyl group connected to —O— attached to R10 is substituted with methyl;
R1 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2;
R2 is —CH(CH3)OH;
R3 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2;
the amino acid at position-3 is L-configuration,
R4 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2;
R5 is —CH2—R11; R11 is phenyl;
the amino acid at position-6 is D-configuration,
R6 is (C3-C8)-branched alkyl, for example, isobutyl;
R7 is NH2—(CH2)y—, wherein y is an integer from 1 to 4, for example, 2;
R8 is NH2—(CH2)y—, wherein y is an integer from 1 to 4, for example, 2; and
R9 is —CH(CH3)OH.

### Claim at position 4

5: A polymyxin derivative or a pharmaceutically acceptable salt thereof,
wherein R0 is selected from the group consisting of (C7-C12)-branched alkyl group, for example 5-methylheptyl, (S)-5-methylheptyl;
R1 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2;
R2 is —CH(CH3)OH;
R3 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2;
the amino acid at position-3 is L-configuration,
R4 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2;
R5 is —CH2—R11; R11 is selected from the group consisting of:
R12 is selected from the group consisting of —NH2, —OH, —CN, —NO2, —F, —Cl, —Br, —CF3, CH3—O—, CH3—CH2—O—, (C1-C4)-linear chain alkyl or (C3-C4)-branched alkyl group,-benzyl group,-benzoyl group; R13 and R14 are selected from the group consisting of H, —F, —Cl, —Br;
the amino acid at position-6 is D-configuration,
R6 is (C3-C8)-branched alkyl, for example, isobutyl;
R7 is NH2—(CH2)y—, wherein y is an integer from 1 to 4, for example, 2;
R8 is NH2—(CH2)y—, wherein y is an integer from 1 to 4, for example, 2;
R9 is —CH(CH3)OH; and
wherein compound 12 is not included.

### Claim at position 5

6: A polymyxin derivative or a pharmaceutically acceptable salt thereof,
wherein, R0 is selected from the group consisting of: (C6-C11)-linear alkyl, for example, hexyl, heptyl, octyl, (C7-C12)-branched alkyl, for example 5-methylheptyl, 5-methylhexyl, (S)-5-methylheptyl group;
R1 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2;
R2 is —CH(CH3)OH or —CH2OH, for example (R)—CH(CH3)OH;
R3 is —CH2OH, the amino acid at position-3 is D-configuration
R4 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2;
R5 is —CH2—R11; R11 is phenyl;
the amino acid at position-6 is D-configuration,
R6 is —CH(CH3)OH or —CH2OH, for example (R)—CH(CH3)OH;
R7 is NH2—(CH2)y—, wherein y is an integer from 1 to 4, for example, 2; or —CH2OH;
R8 is NH2—(CH2)y—, wherein y is an integer from 1 to 4, for example, 2; or —CH2OH;
R9 is —CH(CH3)OH or —CH2OH, for example (R)—CH(CH3)OH; and
wherein compound 115 is not included.

### Claim at position 6

7: A polymyxin derivative or a pharmaceutically acceptable salt thereof,
wherein R0 is selected from the group consisting of (C7-C12)-branched alkyl group, for example 5-methylheptyl, 5-methylhexyl, (S)-5-methylheptyl, (C6-C11)linear alkyl, for example, hexyl, heptyl, octyl;
R1 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2; or —CH2OH;
R2 is —CH(CH3)OH or —CH2OH, for example (R)—CH(CH3)OH;
R3 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2; the amino acid at position-3 is D-configuration;
R4 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2; or —CH2OH;
R5 is selected from the group consisting of: (C3-C8)-branched alkyl, for example, isobutyl, —CH(CH3)OH, for example, (R)—CH(CH3)OH, the amino acid at position-6 is D or L-configuration;
R6 is —CH(CH3)OH, for example, (R)—CH(CH3)OH or —CH2OH;
R7 is NH2—(CH2)y—, wherein y is an integer from 1 to 4, for example, 2; or —CH2OH;
R8 is NH2—(CH2)y—, wherein y is an integer from 1 to 4, for example, 2; or —CH2OH;
R9 is —CH(CH3)OH; and
wherein compounds 30 and 31 are not included.

### Claim at position 7

8: A polymyxin derivative or a pharmaceutically acceptable salt thereof, wherein the polymyxin derivative is selected from the group consisting of Compounds 1 to 152, excluding compounds 8, 10, 12, 30, 31, 42, 43, 44, 45, 46, 47, 58, 59, 70, 71, 72, 73, 74, 75, 76, 77, 78, 82, 86, 102, 103, 115, 127, 128, 143, 144.

### Claim at position 8 (depends on 3)

9: A pharmaceutical composition-comprising a polymyxin derivative according to claim 3, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

### Claim at position 9 (depends on 3)

10: Use of a polymyxin derivative according to claim 3 or a pharmaceutically acceptable salt thereof in the preparation of an antibacterial agent, in particular in the preparation of an antibacterial against “superbugs” carrying the NDM-1 gene use in medicine.

### Claim at position 10 (depends on 3)

11: A method of preparing a compound according to claim 3 comprising the steps of:
(1) The side chain free amino group in the protected basic amino acid Fmoc-AA-OP and halogenated resin are reacted to obtain Fmoc-AA-OP-resin; P is a carboxyl protecting group, for example, allyl group, benzyl group; when AA-OP is Fmoc-Dab-OP, its structure is as shown in Formula III; when Fmoc-AA-OP is Fmoc-Dap-OP, its structure is as shown in Formula IV:
(2) Fmoc-AA-OP-resin is coupled one by one to obtain a linear polypeptide-resin;
(3) By selectively removing the protecting group from the linear polypeptide-resin, and solid-phase cyclizing to obtain a cyclic polypeptide-resin;
(4) The cyclic polypeptide-resin is acid hydrolysed to obtain a crude cyclic polypeptide;
(5) The crude cyclic polypeptide is purified and/or salified, and lyophilized to obtain a pure cyclic polypeptide.

### Claim at position 11 (depends on 11)

12: The method according to claim 11, wherein DIC/HOBT is used as a condensing agent without adding a base as a catalyst.

### Claim at position 12

13: A polymyxin derivative having the structure of the formula II or a pharmaceutically acceptable salt thereof,
wherein R0 is selected from the group consisting of: (C7-C12)-branched alkyl, for example, 5-methylheptyl, 5-methylhexyl, (S)-5-methylheptyl, (C6-C11)-linear alkyl, for example, hexyl, heptyl, octyl;
R1 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2; or —CH2OH;
R2 is —CH(CH3)OH or —CH2OH, for example (R)—CH(CH3)OH;
R3 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2; or —CH2OH;
the position-3 amino acid is L-configuration;
R4 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2; or —CH2OH;
R5 is selected from the group consisting of —CH2—R11, R11 is phenyl; (R)—CH(CH3)OH;
the position-6 amino acid is D or L-configuration;
R6 is (C3-C8) branched alkyl, for example, sec-butyl, isobutyl;
R7 is NH2—(CH2)y—, y is an integer from 1 to 4, for example, 2; or —CH2OH;
R8 is NH2—(CH2)y—, y is an integer from 1 to 4, for example, 2; or —CH2OH;
R9 is —CH(CH3)OH or —CH2OH, for example (R)—CH(CH3)OH; and
compounds 42, 43, 44, 45, 46, 47 are not included.

### Claim at position 13

14: A polymyxin derivative having the structure of the formula II or a pharmaceutically acceptable salt thereof,
wherein R0 is selected from the group consisting of: (C7-C12) branched alkyl, for example, 5-methylheptyl, 5-methylhexyl, (S)-5-methylheptyl, (C6-C11) linear alkyl, for example, hexyl, heptyl, octyl;
R1 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2; —CH2OH,
R2 is —CH(CH3)OH or —CH2OH, for example (R)—CH(CH3)OH;
R3 is —CH2OH, the position-3 amino acid is D-configuration;
R4 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2; or —CH2OH;
R5 is (C3-C8) branched alkyl, for example, isobutyl, The position-6 amino acid is D-configuration;
R6 is —CH(CH3)OH or —CH2OH, for example (R)—CH(CH3)OH;
R7 is NH2—(CH2)y—, y is an integer from 1 to 4, for example 2; —CH2OH;
R8 is NH2—(CH2)y—, y is an integer from 1 to 4, for example 2; —CH2OH;
R9 is —CH(CH3)OH or —CH2OH, for example (R)—CH(CH3)OH; and
compounds 58, 59 are not included.

### Claim at position 14

15: A polymyxin derivative having the structure of the formula II or a pharmaceutically acceptable salt thereof,
wherein, R0 is selected from the group consisting of: (C6-C11) linear alkyl, for example, hexyl, heptyl, (C7-C12) branched alkyl, for example, 5-methylheptyl, 5-methylhexyl, 6-methylheptyl, (S)-5-methylheptyl;
R1 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2; or —CH2OH;
R2 is —CH(CH3)OH or —CH2OH, for example, (R)—CH(CH3)OH;
R3 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2; or —CH2OH, the position-3 amino acid is L-configuration;
R4 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2; or —CH2OH;
R5 is (C3-C8) branched alkyl, for example, isobutyl, the position-6 amino acid is D-configuration;
R6 is (C1-C8) linear alkyl, for example, propyl, or (C3-C8)-branched alkyl, for example, isobutyl, sec-butyl or isopropyl;
R7 is NH2—(CH2)y—, y is an integer from 1 to 4, for example, 2; or —CH2OH;
R8 is NH2—(CH2)y—, y is an integer from 1 to 4, for example, 2; or —CH2OH;
R9 is —CH(CH3)OH or —CH2OH, for example, (R)—CH(CH3)OH; and
compounds 70, 71, 72, 73, 74, 75, 76, 77, 78, 82, 86 are not included.

### Claim at position 15

16: A polymyxin derivative having the structure of the formula II or a pharmaceutically acceptable salt thereof,
wherein, R0 is selected from the group consisting of: (C6-C11) linear alkyl, for example, hexyl, heptyl, octyl, (C7-C12) branched alkyl, for example, 5-methylheptyl, 5-methylhexyl, (S)-5-methylheptyl;
R1 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2; or —CH2OH;
R2 is —CH(CH3)OH or —CH2OH, for example —CH(CH3)OH;
R3 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2; or —CH2OH;
the position-3 amino acid is L-configuration;
R4 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2; or —CH2OH;
R5 is (C3-C8) branched alkyl, for example isobutyl;
the position-6 amino acid is D-configuration;
R6 is —CH(CH3)OH or —CH2OH, for example, (R)—CH(CH3)OH;
R7 is NH2—(CH2)y—, y is an integer from 1 to 4, for example, 2; or —CH2OH;
R8 is NH2—(CH2)y—, y is an integer from 1 to 4, for example, 2; or —CH2OH;
R9 is —CH(CH3)OH or —CH2OH, for example (R)—CH(CH3)OH; and
compounds 102, 103 are not included in this embodiment.

### Claim at position 16

17: A polymyxin derivative having the structure of the formula II or a pharmaceutically acceptable salt thereof,
wherein, R0 is selected from the group consisting of: (C6-C11) linear alkyl, for example, hexyl, heptyl, octyl, (C7-C12) branched alkyl, for example 5-methylheptyl, 5-methylhexyl, (S)-5-methylheptyl;
R1 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2; or —CH2OH;
R2 is —CH(CH3)OH or —CH2OH, for example (R)—CH(CH3)OH;
R3 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2; —CH2OH;
the position-3 amino acid is L-configuration;
R4 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2; or —CH2OH;
R5 is —CH2—R11; R11 is phenyl;
the position-6 amino acid is D-configuration;
R6 is (C3-C8) branched alkyl, for example isobutyl;
R7 is NH2—(CH2)y—, y is an integer from 1 to 4, for example, 2; or —CH2OH;
R8 is NH2—(CH2)y—, y is an integer from 1 to 4, for example, 2; or —CH2OH;
R9 is (C3-C4) branched alkyl, for example, isobutyl; and
compounds 127 and 128 are not included.

### Claim at position 17

18: A polymyxin derivative having the structure of the formula II or a pharmaceutically acceptable salt thereof,
wherein, R0 is selected from the group consisting of: (C6-C11) linear alkyl, for example, heptyl, hexyl, octyl, (C7-C12) branched alkyl, for example, 5-methylheptyl, (S)-5-methylheptyl, 5-methylhexyl;
R1 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2;
R2 is —CH(CH3)OH for example, (R)—CH(CH3)OH;
R3 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2;
the position-3 amino acid is L-configuration;
R4 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2;
R5 is —CH2—R11; R11 is phenyl;
the position-6 amino acid is L-configuration;
R6 is —CH(CH3)OH for example, (R)—CH(CH3)OH;
R7 is NH2—(CH2)y—, wherein y is an integer from 1 to 4, for example, 2;
R8 is NH2—(CH2)y—, wherein y is an integer from 1 to 4, for example, 2; and
R9 is —CH(CH3)OH for example, (R)—CH(CH3)OH.

### Claim at position 18

19: A polymyxin derivative having the structure of the formula II or a pharmaceutically acceptable salt thereof,
wherein, R0 is selected from the group consisting of: (C6-C11) linear alkyl, for example, heptyl, hexyl, octyl, (C7-C12) branched alkyl, for example, 5-methylheptyl, 5-methylhexyl, (S)-5-methylheptyl;
R1 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2;
R2 is —CH(CH3)OH for example, (R)—CH(CH3)OH;
R3 NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2; the position-3 amino acid is D-configuration;
R4 is NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2;
R5 is —CH2—R11; R11 is phenyl;
the position-6 amino acid is D-configuration;
R6 is —CH(CH3)OH for example, (R)—CH(CH3)OH;
R7 is NH2—(CH2)y—, wherein y is an integer from 1 to 4, for example, 2;
R8 is NH2—(CH2)y—, wherein y is an integer from 1 to 4, for example, 2;
R9 is —CH(CH3)OH for example, (R)—CH(CH3)OH; and
compounds 143, 144 are not included in this embodiment.

### Claim at position 19

20: A polymyxin derivative having the structure of the formula II or a pharmaceutically acceptable salt thereof,
wherein, R0 is selected from the group consisting of: (C6-C11) linear alkyl groups, for example, heptyl groups;
R1 is —CH(CH3)OH, for example (R)—CH(CH3)OH; NH2(CH2)x—, wherein x is an integer from 1 to 4, for example, 1; NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2; NH2C(═NH)NH(CH2)x—, wherein x is an integer from 1 to 4, for example, 3;
R2 is —CH(CH3)OH for example, (R)—CH(CH3)OH;
R3 is —CH(CH3)OH for example, (R)—CH(CH3)OH; NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2; —(CH2)2SCH3;
the position-3 amino acid is L-configuration;
R4 is an integer of NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 2; NH2—(CH2)x—, wherein x is an integer from 1 to 4, for example, 1;
R5 is —CH2—R11; R11 is phenyl;
the position-6 amino acid is D-configuration;
R6 is (C3-C8)-branched alkyl, for example isobutyl;
R7 is NH2—(CH2)y—, y is an integer from 1 to 4, for example, 2; NH2—(CH2)y—, y is an integer from 1 to 4, for example, 1;
R8 is NH2—(CH2)y—, y is an integer from 1 to 4, for example, 2; NH2—(CH2)y—, y is an integer from 1 to 4, for example, 1; and
R9 is —CH(CH3)OH for example, (R)—CH(CH3)OH.
